Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis

The Lancet Infectious Diseases - Tập 16 - Trang 828-837 - 2016
Francisco M Marty1, Luis Ostrosky-Zeichner2, Oliver A Cornely3, Kathleen M Mullane4,5, John R Perfect6,7, George R Thompson8,9, George J Alangaden10, Janice M Brown11, David N Fredricks12, Werner J Heinz13, Raoul Herbrecht14, Nikolai Klimko15, Galina Klyasova16, Johan A Maertens17, Sameer R Melinkeri18, Ilana Oren19, Peter G Pappas20, Zdeněk Ráčil21, Galia Rahav22, Rodrigo Santos23
1Division of Infectious Diseases, Brigham and Women's Hospital, Boston, MA, USA
2University of Texas Medical School at Houston and Memorial Hermann Texas Medical Center, University of Texas, Houston, TX, USA
3Department I of Internal Medicine, Clinical Trials Centre Cologne, ZKS Köln, Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases, University of Cologne, Cologne, Germany
4Department of Medicine, University of Chicago, IL, USA
5Division of Infectious Diseases, University of Chicago, IL, USA
6Department of Medicine, Duke University, Durham, NC, USA
7Division of Infectious Diseases, Duke University, Durham, NC, USA
8Departments of Medicine, University of California, Davis, CA, USA
9Division of Infectious Diseases and Medical Microbiology and Immunology, University of California, Davis, CA, USA
10Division of Infectious Diseases, Department of Internal Medicine, Henry Ford Hospital, Detroit, MI, USA
11Division of Blood and Marrow Transplantation, Stanford University Medical Center, Stanford, CA, USA
12Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
13University of Würzburg Medical Centre, Würzburg, Germany
14Department of Oncology and Hematology, Hautepierre Hospital, University of Strasbourg, Strasbourg, France
15North Western State Medical University, St Petersburg, Russia
16National Research Center for Hematology, Moscow, Russia
17Department of Hematology, University Hospital Gasthuisberg, Leuven, Belgium
18Deenanath Mangeshkar Hospital and Research Centre, Erandawane, Pune, India
19Unit of Infectious Diseases, Rambam Health Care Campus, Haifa, Israel
20Division of Infectious Diseases, University of Alabama at Birmingham, AL, USA
21University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic
22Infectious Disease Unit, Sheba Medical Center, Tel Hashomer, Israel
23Federal University of Minas Gerais, Belo Horizonte, Minas Gerais, Brazil

Tài liệu tham khảo

Roden, 2005, Epidemiology and outcome of zygomycosis: a review of 929 reported cases, Clin Infect Dis, 41, 634, 10.1086/432579 Kontoyiannis, 2010, Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001–2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database, Clin Infect Dis, 50, 1091, 10.1086/651263 Skiada, 2011, Zygomycosis in Europe: analysis of 230 cases accrued by the registry of the European Confederation of Medical Mycology (ECMM) Working Group on Zygomycosis between 2005 and 2007, Clin Microbiol Infect, 17, 1859, 10.1111/j.1469-0691.2010.03456.x Chamilos, 2008, Delaying amphotericin B-based frontline therapy significantly increases mortality among patients with hematologic malignancy who have zygomycosis, Clin Infect Dis, 47, 503, 10.1086/590004 Cornely, 2014, ESCMID and ECMM joint clinical guidelines for the diagnosis and management of mucormycosis 2013, Clin Microbiol Infect, 20, 5, 10.1111/1469-0691.12371 Almyroudis, 2007, In vitro susceptibilities of 217 clinical isolates of zygomycetes to conventional and new antifungal agents, Antimicrob Agents Chemother, 51, 2587, 10.1128/AAC.00452-07 Sabatelli, 2006, In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts, Antimicrob Agents Chemother, 50, 2009, 10.1128/AAC.00163-06 Walsh, 2004, Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia, N Engl J Med, 351, 1391, 10.1056/NEJMoa040446 Greenberg, 2006, Posaconazole as salvage therapy for zygomycosis, Antimicrob Agents Chemother, 50, 126, 10.1128/AAC.50.1.126-133.2006 van Burik, 2006, Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases, Clin Infect Dis, 42, e61, 10.1086/500212 Miceli, 2015, Isavuconazole: a new broad-spectrum triazole antifungal agent, Clin Infect Dis, 61, 1558, 10.1093/cid/civ571 De Pauw, 2008, Clin Infect Dis, 46, 1813, 10.1086/588660 Rüping, 2010, Forty-one recent cases of invasive zygomycosis from a global clinical registry, J Antimicrob Chemother, 65, 296, 10.1093/jac/dkp430 Chakrabarti, 2010, Apophysomyces elegans: epidemiology, amplified fragment length polymorphism typing, and in vitro antifungal susceptibility pattern, J Clin Microbiol, 48, 4580, 10.1128/JCM.01420-10 Lanternier, 2012, A global analysis of mucormycosis in France: the RetroZygo Study (2005–2007), Clin Infect Dis, 54, S35, 10.1093/cid/cir880 Shoham, 2010, Primary treatment of zygomycosis with liposomal amphotericin B: analysis of 28 cases, Med Mycol, 48, 511, 10.3109/13693780903311944 Singh, 2009, Zygomycosis in solid organ transplant recipients: a prospective, matched case-control study to assess risks for disease and outcome, J Infect Dis, 200, 1002, 10.1086/605445 Segal, 2008, Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria, Clin Infect Dis, 47, 674, 10.1086/590566 2008 Maertens, 2016, Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial, Lancet, 387, 760, 10.1016/S0140-6736(15)01159-9 Kara, 2009, Mucormycosis-associated fungal infections in patients with haematologic malignancies, Int J Clin Pract, 63, 134, 10.1111/j.1742-1241.2006.01145.x Lanternier, 2015, Prospective pilot study of high-dose (10 mg/kg/day) liposomal amphotericin B (L-AMB) for the initial treatment of mucormycosis, J Antimicrob Chemother, 70, 3116, 10.1093/jac/dkv236 Herbrecht, 2002, Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis, N Engl J Med, 347, 408, 10.1056/NEJMoa020191 Lewis, 2014, Comparative pharmacodynamics of posaconazole in neutropenic murine models of invasive pulmonary aspergillosis and mucormycosis, Antimicrob Agents Chemother, 58, 6767, 10.1128/AAC.03569-14 Luo, 2014, Isavuconazole therapy protects immunosuppressed mice from mucormycosis, Antimicrob Agents Chemother, 58, 2450, 10.1128/AAC.02301-13 Luo, 2013, Efficacy of liposomal amphotericin B and posaconazole in intratracheal models of murine mucormycosis, Antimicrob Agents Chemother, 57, 3340, 10.1128/AAC.00313-13 Bacher, 2015, Fungus-specific CD4(+) T cells for rapid identification of invasive pulmonary mold infection, Am J Respir Crit Care Med, 191, 348, 10.1164/rccm.201407-1235LE Koo, 2014, A breath fungal secondary metabolite signature to diagnose invasive aspergillosis, Clin Infect Dis, 59, 1733, 10.1093/cid/ciu725 Millon, 2013, Quantitative polymerase chain reaction detection of circulating DNA in serum for early diagnosis of mucormycosis in immunocompromised patients, Clin Infect Dis, 56, e95, 10.1093/cid/cit094
Thông tin
Thông tin xuất bản

The Lancet Infectious Diseases

Tập 16

828-837

Thông tin tác giả